Hong N, Shin S, Lee S, Rhee Y, et al. Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis. Osteoporos Int 2023 Aug 19. doi: 10.1007/s00198-023-06889.
PMID: 37596432